English
简体中文
繁體中文
English
Filipino
हिन्दी
Hmong
Bahasa Indonesia
日本語
Basa Jawa
한국어
ພາສາລາວ
Bahasa Melayu
മലയാളം
ဗမာစာ
سنڌي
தமிழ்
ไทย
Tiếng Việt
Afrikaans
Shqip
العربية
አማርኛ
Հայերեն
Azərbaycan dili
Euskara
Беларуская мова
বাংলা
Bosanski
Български
Català
Cebuano
Chichewa
Corsu
Italiano
Hrvatski
Čeština
Dansk
Nederlands
Esperanto
Eesti
Suomi
Frysk
Galego
ქართული
Ελληνικά
ગુજરાતી
Kreyol ayisyen
Deutsch
Français
Harshen Hausa
Ōlelo Hawaiʻi
עִבְרִית
Magyar
Íslenska
Igbo
Gaeilge
ಕನ್ನಡ
Қазақ тілі
ភាសាខ្មែរ
كوردی
Кыргызча
Latin
Latviešu valoda
Lietuvių kalba
Lëtzebuergesch
Македонски јазик
Malagasy
Maltese
Te Reo Māori
मराठी
Монгол
नेपाली
Norsk bokmål
پښتو
فارسی
Polski
Português
ਪੰਜਾਬੀ
Română
Русский
Samoan
Gàidhlig
Српски језик
Sesotho
Shona
සිංහල
Slovenčina
Slovenščina
Afsoomaali
Español
Basa Sunda
Kiswahili
Svenska
Тоҷикӣ
తెలుగు
Türkçe
Українська
اردو
O‘zbekcha
Cymraeg
isiXhosa
יידיש
Yorùbá
ZuluSwiss dental implants company Straumann has raised its 2022 organic sales growth outlook, suggesting post-pandemic recovery is on the cards.
“Very good” quarter despite uncertainties
Against its earlier low-double-digit percentage growth forecast, Straumann raised its revenue to organically grow in the mid-teens percentage range.
The third-quarter organic sales for the dental implants company came in at 551 million Swiss francs ($552 million), representing a 12% increase as compared to last year.
“We were able to deliver a very good quarter despite the ongoing macro-economic uncertainties,” said Guillaume Daniellot, Straumann’s chief executive.
Straumann confirmed its full-year guidance for core earnings before interest and taxes (EBIT) margin of around 26%, including significant growth investments.
Optimism from easing lockdowns
US dental care providers that benefited from last year’s increased demand for specialty treatments following the easing of COVID-19-related lockdowns, are finding assurance in early signs that its core market in China is lifting its lockdown restrictions.
China represents more than half of Straumann’s overall business in the Asia-Pacific region, where sales grew by almost 9% organically in the third quarter.
About the Straumann Group
The Straumann Group develops, manufactures and supplies dental implants, instruments, biomaterials, CAD/CAM prosthetics, digital equipment, software, and clear aligners for applications in replacement, restorative, orthodontic and preventative dentistry.
Its products and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.
The information and viewpoints presented in the above news piece or article do not necessarily reflect the official stance or policy of Dental Resource Asia or the DRA Journal. While we strive to ensure the accuracy of our content, Dental Resource Asia (DRA) or DRA Journal cannot guarantee the constant correctness, comprehensiveness, or timeliness of all the information contained within this website or journal.
Please be aware that all product details, product specifications, and data on this website or journal may be modified without prior notice in order to enhance reliability, functionality, design, or for other reasons.
The content contributed by our bloggers or authors represents their personal opinions and is not intended to defame or discredit any religion, ethnic group, club, organisation, company, individual, or any entity or individual.